Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022

GlobeNewswire March 24, 2022

Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting

GlobeNewswire March 8, 2022

Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 16, 2022

AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

PR Newswire January 7, 2022

Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire January 5, 2022

Calithera to Present at the 2021 Jefferies London Healthcare Conference

GlobeNewswire November 12, 2021

Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

GlobeNewswire November 9, 2021

Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer

GlobeNewswire November 5, 2021

Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

GlobeNewswire November 5, 2021

Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

GlobeNewswire November 2, 2021

Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021

GlobeNewswire November 1, 2021

Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021

GlobeNewswire October 21, 2021

Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals

GlobeNewswire October 18, 2021

Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer

GlobeNewswire September 8, 2021

Calithera Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 2, 2021

Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

GlobeNewswire August 5, 2021

Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

GlobeNewswire July 29, 2021

Final Data from Calithera Biosciences' Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting

GlobeNewswire June 7, 2021

Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference

GlobeNewswire May 27, 2021

Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

GlobeNewswire May 17, 2021